NewBridge Pharmaceuticals
Newbridge's core therapeutic areas of focus are oncology, cardiology, neurology, and rare diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | $48.0m | Series C | |
| Total Funding | 000k | ||
Related Content
NewBridge Pharmaceuticals is a specialty healthcare company focused on bridging the gap between global innovation and the MENA (Middle East and North Africa) region. The company provides a one-stop solution for pharmaceutical, biological, genomic, and other innovative healthcare companies seeking to access the MENA markets. NewBridge serves patients by offering advanced treatment options and addressing unmet medical needs in the region.
Operating in over 20 countries within the MENA region, NewBridge leverages its extensive global business network to provide essential access to innovative therapeutics and diagnostics. The company partners with leading pharmaceutics and biotech firms to bring cutting-edge healthcare solutions to the market.
NewBridge's business model revolves around forming strategic partnerships with global healthcare innovators, enabling them to penetrate the MENA market effectively. The company generates revenue through these partnerships by facilitating the distribution and commercialization of advanced healthcare products.
Clients of NewBridge include pharmaceutical companies, biotech firms, and healthcare providers looking to expand their reach in the MENA region. The company’s unique value proposition lies in its ability to navigate the complex regulatory landscape and provide market access solutions tailored to the needs of its partners.
Keywords: specialty healthcare, MENA region, pharmaceutical, biological, genomic, innovative healthcare, advanced treatment, market access, strategic partnerships, unmet medical needs.